Showing results (61-70 of 76) with videos related to
Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB studyValentina Guarneri, Antonio Frassoldati, Alberto Bottini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2023
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized TrialPierFranco Conte, Giancarlo Bisagni, Federico Piacentini, et al.Future Oncology (London, England)|July 6, 2022
Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experienceFrancesco Caputo, Chiara Santini, Andrea Casadei-Gardini, et al.JAMA Oncology|February 13, 2025
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical TrialMaria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, et al.The Lancet. Oncology|November 25, 2015
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trialJavier Cortés, Véronique Dieras, Jungsil Ro, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2025
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trialFederica Miglietta, Manon De Graaf, Claudio Vernieri, et al.British Journal of Cancer|November 17, 2022
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluationMaria Vittoria Dieci, Luisa Carbognin, Federica Miglietta, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2020
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 SubtypeValentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, et al.Frontiers in Oncology|July 13, 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative studyAgnese Fabbri, Fabrizio Nelli, Andrea Botticelli, et al.BMC Cancer|June 15, 2024
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER studyFabio Canino, Monica Barbolini, Ugo De Giorgi, et al.Pageof 8